StockMarketWire.com - PureTech Health said subsidiary Vedanta Biosciences had released data showing that a product candidate had induced an anti-tumour response.
The treatment, VE800, is an orally-administered, live biotherapeutic product candidate in immuno-oncology.
Pre-clinical data showed it induced a systemic anti-tumour immune response both as a monotherapy and in combination with checkpoint inhibitors.
The data would be presented at the Society for Immunotherapy of Cancer's annual meeting on 8 November.
At 1:37pm: [LON:PRTC] PureTech Health Plc share price was +4.5p at 167p
Story provided by StockMarketWire.com
Shares Magazine
Shares is the leading weekly publication for retail investors. It is packed with investment ideas, news and educational material to help build and run portfolios and get more from your money.
Investor Events
Shares puts on free Investor Events throughout the year across the country. They provide an opportunity for investors to learn more about companies on the stock market and hear from a range of investment experts including fund managers and Shares journalists.